LAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expression

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTEIXEIRA, Franciane Mouradian Emidio
dc.contributor.authorOLIVEIRA, Luana de Mendonca
dc.contributor.authorPIETROBON, Anna Julia
dc.contributor.authorSALLES, Erika Machado de
dc.contributor.authorLIMA, Maria Regina D'Imperio
dc.contributor.authorVIANA, Isabelle Freire Tabosa
dc.contributor.authorLINS, Roberto Dias
dc.contributor.authorRIGATO, Paula Ordonhez
dc.contributor.authorMARQUES, Ernesto Torres de Azevedo
dc.contributor.authorDUARTE, Alberto Jose da Silva
dc.contributor.authorSATO, Maria Notomi
dc.date.accessioned2022-10-26T14:36:00Z
dc.date.available2022-10-26T14:36:00Z
dc.date.issued2022
dc.description.abstractNeonates have a limited adaptive response of plasma cells, germinal center (GC) B cells, and T follicular helper cells (T-FH). As neonatal vaccination can be an important tool for AIDS prevention, these limitations need to be overcome. Chimeric DNA vaccine encoding p55Gag HIV-1 protein conjugated with lysosomal-associated membrane protein 1 (LAMP-1) has been described as immunogenic in the neonate period. Herein, we investigated the immunologic mechanisms involved in neonatal immunization with a LAMP-1/p55Gag (LAMP/Gag) DNA vaccine in a C57BL/6 mouse background. Neonatal LAMP/Gag vaccination induced strong Gag-specific T-cell response until adulthood and elevated levels of anti-Gag IgG antibodies. We also demonstrated for the first time that the immunogenicity of the neonatal period with LAMP/Gag is due to the induction of high-affinity anti-p24 IgG antibodies and long-term plasma cells. Together with that, there is the generation of early TFH cells and the formation of GC sites with the upregulation of activation-induced cytidine deaminase (AID) enzyme mRNA and protein expression in draining lymph nodes after neonatal LAMP/Gag vaccination. These findings underscore that the LAMP-1 strategy in the chimeric vaccine could be useful to enhance antibody production even in the face of neonatal immaturity, and they contribute to the development of new vaccine approaches for other emerging pathogens at an early stage of life.eng
dc.description.indexPubMedeng
dc.description.sponsorshipLaboratorio de Investigacao Medica, Unidade , Department of Dermatology, School of Medicine, University of Sao Paulo, Brazil
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/18230-6, 2017/18199-9, 2019/25119-7]
dc.identifier.citationVACCINES, v.10, n.8, article ID 1246, 14p, 2022
dc.identifier.doi10.3390/vaccines10081246
dc.identifier.eissn2076-393X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/49357
dc.language.isoeng
dc.publisherMDPIeng
dc.relation.ispartofVaccines
dc.rightsopenAccesseng
dc.rights.holderCopyright MDPIeng
dc.subjectDNA vaccineeng
dc.subjectneonateeng
dc.subjectHIVeng
dc.subjectimmunogenicityeng
dc.subjectgerminal centereng
dc.subject.othert-cell responseseng
dc.subject.othermembrane-proteineng
dc.subject.otherdouble-blindeng
dc.subject.othermediated-immunityeng
dc.subject.otherii compartmenteng
dc.subject.otherhelper-cellseng
dc.subject.othervaccineeng
dc.subject.othergageng
dc.subject.otherdnaeng
dc.subject.otherefficacyeng
dc.subject.wosImmunologyeng
dc.subject.wosMedicine, Research & Experimentaleng
dc.titleLAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expressioneng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalSALLES, Erika Machado de:Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalLIMA, Maria Regina D'Imperio:Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, Brazil
hcfmusp.author.externalVIANA, Isabelle Freire Tabosa:Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol, BR-50740465 Recife, PE, Brazil
hcfmusp.author.externalLINS, Roberto Dias:Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol, BR-50740465 Recife, PE, Brazil
hcfmusp.author.externalRIGATO, Paula Ordonhez:Adolfo Lutz Inst, Ctr Immunol, Lab Immunobiol & Biomarkers, BR-01246000 Sao Paulo, Brazil
hcfmusp.author.externalMARQUES, Ernesto Torres de Azevedo:Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Dept Virol, BR-50740465 Recife, PE, Brazil; Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA
hcfmusp.citation.scopus2
hcfmusp.contributor.author-fmusphcFRANCIANE MOURADIAN EMIDIO TEIXEIRA
hcfmusp.contributor.author-fmusphcLUANA DE MENDONCA OLIVEIRA
hcfmusp.contributor.author-fmusphcANNA JULIA PIETROBON
hcfmusp.contributor.author-fmusphcALBERTO JOSE DA SILVA DUARTE
hcfmusp.contributor.author-fmusphcMARIA NOTOMI SATO
hcfmusp.description.articlenumber1246
hcfmusp.description.issue8
hcfmusp.description.volume10
hcfmusp.origemWOS
hcfmusp.origem.pubmed36016134
hcfmusp.origem.scopus2-s2.0-85137413311
hcfmusp.origem.wosWOS:000845165700001
hcfmusp.publisher.cityBASELeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAddo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003eng
hcfmusp.relation.reference[Anonymous], GLOB HIV AIDS STAT Feng
hcfmusp.relation.referenceArruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265eng
hcfmusp.relation.referenceBuchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3eng
hcfmusp.relation.referenceBUSEYNE F, 1994, CLIN EXP IMMUNOL, V97, P353eng
hcfmusp.relation.referenceCapozzo AVE, 2006, J IMMUNOL, V176, P5671, DOI 10.4049/jimmunol.176.9.5671eng
hcfmusp.relation.referenceChikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135eng
hcfmusp.relation.referenceChung AW, 2018, AIDS, V32, P1207, DOI 10.1097/QAD.0000000000001812eng
hcfmusp.relation.referenceCinicola B, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.638871eng
hcfmusp.relation.referenceDe Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.xeng
hcfmusp.relation.referencede Brito CA, 2009, IMMUNOTHERAPY-UK, V1, P883, DOI 10.2217/IMT.09.38eng
hcfmusp.relation.referenceDebock I, 2013, J IMMUNOL, V191, P1231, DOI 10.4049/jimmunol.1203288eng
hcfmusp.relation.referenceDuerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342eng
hcfmusp.relation.referenceFlynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404eng
hcfmusp.relation.referenceFu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399eng
hcfmusp.relation.referenceGavillet BM, 2015, J IMMUNOL, V194, P4836, DOI 10.4049/jimmunol.1402071eng
hcfmusp.relation.referenceGoenka A, 2015, J INFECTION, V71, pS112, DOI 10.1016/j.jinf.2015.04.027eng
hcfmusp.relation.referenceGoldoni AL, 2011, IMMUNOBIOLOGY, V216, P505, DOI 10.1016/j.imbio.2010.08.007eng
hcfmusp.relation.referenceGoodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900eng
hcfmusp.relation.referenceGray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6eng
hcfmusp.relation.referenceHassett DE, 2000, J VIROL, V74, P2620, DOI 10.1128/JVI.74.6.2620-2627.2000eng
hcfmusp.relation.referenceHerath S, 2016, VACCINE, V34, P4378, DOI 10.1016/j.vaccine.2016.07.028eng
hcfmusp.relation.referenceJain S., 2021, BIORXIV, DOI [10.1101/2021.06.16.448593, DOI 10.1101/2021.06.16.448593]eng
hcfmusp.relation.referenceJohnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870eng
hcfmusp.relation.referenceKaushik S, 2005, CLIN EXP IMMUNOL, V142, P388, DOI 10.1111/j.1365-2249.2005.02926.xeng
hcfmusp.relation.referenceKeim C, 2013, GENE DEV, V27, P1, DOI 10.1101/gad.200014.112eng
hcfmusp.relation.referenceKLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715eng
hcfmusp.relation.referenceKollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009eng
hcfmusp.relation.referenceKutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432eng
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262eng
hcfmusp.relation.referenceLoeffler FF, 2021, RSC MED CHEM, V12, P1525, DOI 10.1039/d1md00124heng
hcfmusp.relation.referenceLofano G, 2015, J IMMUNOL, V195, P1617, DOI 10.4049/jimmunol.1402604eng
hcfmusp.relation.referenceMa CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994eng
hcfmusp.relation.referenceMaciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693eng
hcfmusp.relation.referenceMarques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200eng
hcfmusp.relation.referenceMastelic B, 2012, J IMMUNOL, V189, P5764, DOI 10.4049/jimmunol.1201143eng
hcfmusp.relation.referenceMata M, 1998, J IMMUNOL, V161, P2985eng
hcfmusp.relation.referenceMunguia-Fuentes R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00013eng
hcfmusp.relation.referenceMuramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7eng
hcfmusp.relation.referenceNorris PJ, 2004, AIDS RES HUM RETROV, V20, P315, DOI 10.1089/088922204322996554eng
hcfmusp.relation.referenceOliveira LMS, 2015, SCI REP-UK, V5, DOI 10.1038/srep13883eng
hcfmusp.relation.referencePetrovas C, 2012, J CLIN INVEST, V122, P3281, DOI 10.1172/JCI63039eng
hcfmusp.relation.referencePihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824eng
hcfmusp.relation.referencePind AAA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02214eng
hcfmusp.relation.referencePitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748eng
hcfmusp.relation.referenceRerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492eng
hcfmusp.relation.referenceRigato PO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031608eng
hcfmusp.relation.referenceRigato PO, 2010, VIROLOGY, V406, P37, DOI 10.1016/j.virol.2010.06.050eng
hcfmusp.relation.referenceRolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519eng
hcfmusp.relation.referenceRuff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671eng
hcfmusp.relation.referenceSchussek S, 2020, MUCOSAL IMMUNOL, V13, P545, DOI 10.1038/s41385-020-0253-2eng
hcfmusp.relation.referenceSedegah M, 2003, J IMMUNOL, V171, P3148, DOI 10.4049/jimmunol.171.6.3148eng
hcfmusp.relation.referenceVono M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00381eng
hcfmusp.relation.referenceWu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005eng
hcfmusp.relation.referenceYu XG, 2002, AIDS, V16, P321, DOI 10.1097/00002030-200202150-00002eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication71a4944c-7ec5-4832-9dd9-d7d5a88b3f93
relation.isAuthorOfPublication53471138-2e04-44a5-a034-d20a7d03ee6b
relation.isAuthorOfPublication3739e25d-6505-4164-aedb-4a04f883180e
relation.isAuthorOfPublication8e4f2c15-06a5-444b-826d-84576403144e
relation.isAuthorOfPublicationc5fbfe7f-eec0-49ea-be33-ce5f13cc3dfb
relation.isAuthorOfPublication.latestForDiscovery71a4944c-7ec5-4832-9dd9-d7d5a88b3f93
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_TEIXEIRA_LAMP1_Chimeric_to_HIV1_p55Gag_in_the_Immunization_2022.PDF
Tamanho:
1.63 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05